ArticleCurrent gastroenterology reports2011
A clinical perspective on gastric neuroendocrine neoplasia.
Article in Current gastroenterology reports, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 35 citations in OpenAlex.
- Gastric Neuroendocrine Tumors According to the 2019 World Health Organization Grading System: A Single-Center, Retrospective Study.Gut and liver · 2023Article
- Endoscopic surveillance alone is feasible and safe in type I gastric neuroendocrine neoplasms less than 10 mm in diameter.Endocrine · 2022Article
- Time to give up traditional methods for the management of gastrointestinal neuroendocrine tumours.World journal of clinical cases · 2021Review
- NETest is superior to chromogranin A in neuroendocrine neoplasia: a prospective ENETS CoE analysis.Endocrine connections · 2021Article
- The NETest liquid biopsy is diagnostic for gastric neuroendocrine tumors: observations on the blood-based identification of microscopic and macroscopic residual diseaseOK.BMC gastroenterology · 2020Article
- Clinical characteristics of early neuroendocrine carcinoma in stomach: A case report and review of literature.Medicine · 2019Article
- Modified AJCC staging of gastric neuroendocrine carcinoma based on T staging can improve the capacity of prognosis assessment.Journal of cancer research and clinical oncology · 2018Article
- Clinicopathological features and outcome for neuroendocrine neoplasms of gastroesophageal junction: A population-based study.Cancer medicine · 2018Article
- CEA Level, Radical Surgery, CD56 and CgA Expression Are Prognostic Factors for Patients With Locoregional Gastrin-Independent GNET.Medicine · 2016Article
- [Endoscopic therapy for gastroduodenal neuroendocrine neoplasms].Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen · 2016Review
- Neuroendocrine Carcinomas of the Gastroenteropancreatic System: A Comprehensive Review.Diagnostics (Basel, Switzerland) · 2015Review
- Decoding the Molecular and Mutational Ambiguities of Gastroenteropancreatic Neuroendocrine Neoplasm Pathobiology.Cellular and molecular gastroenterology and hepatology · 2015Review
- Ki-67 is a reliable pathological grading marker for neuroendocrine tumors.Virchows Archiv : an international journal of pathology · 2013Article
- Endoscopic ultrasonographic assessment of gastric polyps and endoscopic mucosal resection.Current gastroenterology reports · 2012Article
- [Surgery for neuroendocrine tumors of the gastroenteropancreatic system (GEP-NET)].Der Internist · 2012Article
- Current concepts on gastric carcinoid tumors.Gastroenterology research and practice · 2012Article
- The diversity and commonalities of gastroenteropancreatic neuroendocrine tumors.Langenbeck's archives of surgery · 2011Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
The incidence of gastric neuroendocrine tumors (NETs) has increased exponentially based on widespread use of endoscopy and a greater pathological awareness of the condition. A key concern is the potential association with hypergastrinemia induced by proton pump inhibitor administration. Previous confusion regarding diagnosis and therapy has been diminished by a series of international consensus statements defining the biology and management strategies for the disease. Overall, gastric NETs are categorized as well-differentiated or poorly differentiated neoplasms. Well-differentiated gastric NETs are enterochromaffin-like (ECL) cell tumors subclassified into three types based on their relationship to gastrin, a key regulator of ECL cell neoplastic transformation. The treatment of type 1 and type 2 tumors depends on the size and invasiveness of the tumor, whereas type 3 tumors and poorly differentiated neuroendocrine carcinomas warrant aggressive surgical resection. The disease-specific 5-year survival ranges from about 95% in type 1 gastric carcinoids to about 25% in poorly differentiated gastric NECs. Elucidation of the precise biology of a gastric NET is critical to diagnosis and delineation of a type-specific management strategy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.